Genentech Wins FDA Approval for First Adjuvant Therapy for ALK-Positive, Earl...
Pictured: Genentech's sign at its headquarters in California/iStock, Sundry Photography The FDA on Thursday greenlit the use of Genentech’s Alecensa (alectinib) for the adjuvant treatment of patients with early-stage, anaplastic lymphoma kinase- …